291 related articles for article (PubMed ID: 2932197)
1. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
2. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
Maguire ED; Wallis RB
Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
[TBL] [Abstract][Full Text] [Related]
3. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation.
Butler KD; Maguire ED; Smith JR; Turnbull AA; Wallis RB; White AM
Thromb Haemost; 1982 Feb; 47(1):46-9. PubMed ID: 6461944
[TBL] [Abstract][Full Text] [Related]
5. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
6. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
7. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
8. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
[TBL] [Abstract][Full Text] [Related]
9. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors.
Barrett PA; Butler KD; Shand RA; Wallis RB
Thromb Haemost; 1986 Dec; 56(3):311-7. PubMed ID: 3105107
[TBL] [Abstract][Full Text] [Related]
10. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
[TBL] [Abstract][Full Text] [Related]
11. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
12. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
Sincholle D; Coquelet C; Bonne C
Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
[TBL] [Abstract][Full Text] [Related]
14. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
15. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs.
DeCampli WM; Goodwin D; Kosek JC; Handen CE; Mitchell RS; Miller DC
Ann Thorac Surg; 1986 Dec; 42(6):690-6. PubMed ID: 3789860
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
[TBL] [Abstract][Full Text] [Related]
18. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
19. The effects of modulation of prostanoid metabolism on the thoracic platelet accumulation induced by intravenous administration of collagen in the guinea-pig.
Butler KD; Shand RA; Wallis RB
Thromb Haemost; 1986 Dec; 56(3):263-7. PubMed ID: 3105104
[TBL] [Abstract][Full Text] [Related]
20. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
